Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | JUN | P05412 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.51 |
| ▸ | F7 | P08709 | 1/20 | 0.47 |
| ▸ | F3 | P13726 | 1/20 | 0.47 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.47 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.47 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.47 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1515204 | 0.84 | MAPT (0.53) | MAPTRAB9AMAPK1KDM4ENPC1 | |
| SCHEMBL23992178 | 0.83 | TBXAS1 (0.60) | MAPTRAB9AMAPK1KDM4ENPC1 | |
| SCHEMBL3465968 | 0.83 | TBXAS1 (0.49) | MAPTRAB9AMAPK1KDM4ENPC1 | |
| Nicotinaldehyde SCHEMBL28290769 | 0.79 | MAPT (0.56) | MAPTRAB9AMAPK1KDM4ENPC1 | |
| SCHEMBL3092733 | 0.77 | MAPT (0.58) | MAPTRAB9AMAPK1KDM4ENPC1 | |
| SCHEMBL3087230 | 0.77 | JUN (0.45) | KDM4EJUNNFKB1ALDH1A1KMT2A | |
| SCHEMBL176807 | 0.77 | PAM (0.47) | MAPTKDM4EF3ALDH1A1RECQL | |
| SCHEMBL14152431 | 0.76 | MAPT (0.45) | MAPTRAB9AMAPK1KDM4ENPC1 | |
| SCHEMBL2674302 | 0.75 | ADRA2A (0.41) | MAPTKDM4EALDH1A1KMT2ACYP1A2 | |
| SCHEMBL1937380 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200504-A1 | non-peptide NK-3 receptor ligands; anxiety, depression, schizophrenia, obesity; 2-Phenyl-quinoline-4-carboxylic acid (1-pyridin-4-yl-propyl) amide; reacting the 2-phenyl-quinolinyl-4-carbonyl chloride with a pyridylalkylamine to form the amide | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | claimed |
| US-10377745-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-08-13 | — | — | US | disclosed |
| US-20170233377-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-08-17 | — | — | US | disclosed |
| US-9676757-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-20150266862-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| EP-1976560-B1 | THERMOREVERSIBLE OIL-IN-WATER EMULSION | SANOFI PASTEUR (FR) | 2014-01-08 | — | — | EP | disclosed |
| US-8338610-B2 | Pyridinyl compounds useful as intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| EP-1976560-A2 | THERMOREVERSIBLE OIL-IN-WATER EMULSION | Sanofi Pasteur (FR) | 2008-10-08 | — | — | EP | disclosed |
| US-20080200504-A1 | non-peptide NK-3 receptor ligands; anxiety, depression, schizophrenia, obesity; 2-Phenyl-quinoline-4-carboxylic acid (1-pyridin-4-yl-propyl) amide; reacting the 2-phenyl-quinolinyl-4-carbonyl chloride with a pyridylalkylamine to form the amide | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| EP-1915362-A1 | AMIDE ALKYL PYRIDIYL QUINOLINES AS NK3 RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007080308-A2 | THERMOREVERSIBLE OIL-IN-WATER EMULSION | SANOFI PASTEUR (FR) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007018465-A1 | AMIDE ALKYL PYRIDIYL QUINOLINES AS NK3 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233377-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | CACNA1B, CACNG6, SCN5A | MAPT 3375/4885RAB9A 1686/4885MAPK1 1419/4885 |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | MAPT 4650/4885RAB9A 2908/4885MAPK1 973/4885 |
| US-20150266862-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | CACNA1B, CACNG6, SCN5A | MAPT 3375/4885RAB9A 1686/4885MAPK1 1419/4885 |
| US-20080200504-A1 | non-peptide NK-3 receptor ligands; anxiety, depression, schizophrenia, obesity; 2-Phenyl-quinoline-4-carboxylic acid (1-pyridin-4-yl-propyl) amide; reacting the 2-phenyl-quinolinyl-4-carbonyl chloride with a pyridylalkylamine to form the amide | NPY4R, PROKR1, NPSR1 | MAPT 4579/4885RAB9A 1912/4885MAPK1 1859/4885 |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | CCR1, CCRL2, CCR4 | MAPT 4278/4885RAB9A 2271/4885MAPK1 410/4885 |
| US-10377745-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | CACNA1B, CACNG6, SCN5A | MAPT 3375/4885RAB9A 1686/4885MAPK1 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.